It is known that the administration of the NLRP3 inhibitors reduced the severity of the disease in AML [118], DLBCL [119], GvHD [120], multiple myeloma [121], and sickle cell anemia [122] in both vitro and in vivo studies. The gene discussed is NLRP3; the disease is acute myeloid leukemia.